Transhiatal versus transthoracic esophagectomy for esophageal cancer

被引:74
作者
Barreto, J. Camilo [1 ]
Posner, Mitchell C. [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Gen Surg & Surg Oncol, Chicago, IL 60637 USA
关键词
Esophageal cancer; Transhiatal esophageal resection; Transthoracic esophageal resection; PHASE-III TRIAL; HOSPITAL VOLUME; RANDOMIZED-TRIAL; CARCINOMA; SURGERY; RESECTION; ADENOCARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; CHEMORADIATION;
D O I
10.3748/wjg.v16.i30.3804
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Esophageal cancer continues to represent a formidable challenge for both patients and clinicians. Relative 5-year survival rates for patients have improved over the past three decades, probably linked to a combination of improved surgical outcomes, progress in systemic chemotherapy and radiotherapy, and the increasing acceptance of multimodality treatment. Surgical treatment remains a fundamental component of the treatment of localized esophageal adenocarcinoma. Multiple approaches have been described for esophagectomy, which can be thematically grouped under two major categories: either transthoracic or transhiatal. The main controversy rests on whether a more extended resection through thoracotomy provides superior oncological outcomes as opposed to resection with relatively limited morbidity and mortality through a transhiatal approach. After numerous trials have addressed these issues, neither approach has consistently proven to be superior to the other one, and both can provide excellent short-term results in the hands of experienced surgeons. Moreover; the available literature suggests that experience of the surgeon and hospital in the surgical management of esophageal cancer is an important factor for operative morbidity and mortality rates, which could supersede the type of approach selected. Oncological outcomes appear to be similar after both procedures. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:3804 / 3810
页数:7
相关论文
共 45 条
[1]  
Adam DJ, 1996, J ROY COLL SURG EDIN, V41, P371
[2]  
[Anonymous], SEER Cancer statistics review, 1997-2003 Available
[3]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[4]   Impact of hospital volume on operative mortality for major cancer surgery [J].
Begg, CB ;
Cramer, LD ;
Hoskins, WJ ;
Brennan, MF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (20) :1747-1751
[5]   Hospital volume and surgical mortality in the United States. [J].
Birkmeyer, JD ;
Siewers, AE ;
Finlayson, EVA ;
Stukel, TA ;
Lucas, FL ;
Batista, I ;
Welch, HG ;
Wennberg, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) :1128-1137
[6]   Hospital volume and late survival after cancer surgery [J].
Birkmeyer, John D. ;
Sun, Yating ;
Wong, Sandra L. ;
Stukel, Therese A. .
ANNALS OF SURGERY, 2007, 245 (05) :777-783
[7]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[8]  
Bolton John S, 2002, Surg Oncol Clin N Am, V11, P365, DOI 10.1016/S1055-3207(02)00012-1
[9]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[10]   Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [J].
Burmeister, BH ;
Smithers, BM ;
Gebski, V ;
Fitzgerald, L ;
Simes, RJ ;
Devitt, P ;
Ackland, S ;
Gotley, DC ;
Joseph, D ;
Millar, J ;
North, J ;
Walpole, ET ;
Denham, JW .
LANCET ONCOLOGY, 2005, 6 (09) :659-668